Cargando…

A Safety Review and Meta-Analyses of Bevacizumab and Ranibizumab: Off-Label versus Goldstandard

BACKGROUND: We set out a systemic review to evaluate whether off-label bevacizumab is as safe as licensed ranibizumab, and whether bevacizumab can be justifiably offered to patients as a treatment for age-related macular degeneration with robust evidence of no differential risk. METHODS AND FINDINGS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schmucker, Christine, Ehlken, Christoph, Agostini, Hansjuergen T., Antes, Gerd, Ruecker, Gerta, Lelgemann, Monika, Loke, Yoon K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411814/ https://www.ncbi.nlm.nih.gov/pubmed/22880086 http://dx.doi.org/10.1371/journal.pone.0042701

Ejemplares similares

Treatment as Required versus Regular Monthly Treatment in the Management of Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis
por: Schmucker, Christine M., et al.
Publicado: (2015)

Minimal-invasive Katheterverfahren in der Varizentherapie: Neuer Goldstandard?
por: Böhler, Kornelia
Publicado: (2023)

Lasting Controversy on Ranibizumab and Bevacizumab
por: Zou, Lihui, et al.
Publicado: (2011)

Bevacizumab: Off-label use in ophthalmology
por: Grisanti, Salvatore, et al.
Publicado: (2007)

Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells
por: Merz, Patrick R., et al.
Publicado: (2018)

Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation
por: Ratra, Dhanashree, et al.
Publicado: (2021)

Off-label uses of Aflibercept, Ranibizumab and Dexamethasone implant for diabetic retinopathy in Turkey
por: Yilmaz, Mevlut, et al.
Publicado: (2022)

Off-Label Uses of Ranibizumab and Aflibercept for Age-Related Macular Degeneration in Turkey
por: Yilmaz, Mevlut, et al.
Publicado: (2023)

Ranibizumab Injection for Corneal Neovascularization Refractory to Bevacizumab Treatment
por: Ahn, Ye Jin, et al.
Publicado: (2014)

SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB
por: Avery, Robert L., et al.
Publicado: (2017)

Acute anterior uveitis following intravitreal bevacizumab but not subsequent ranibizumab
por: Antonopoulos, Christina, et al.
Publicado: (2011)

Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab
por: Lim, Laurence S, et al.
Publicado: (2015)

Formulation Stabilization and Disaggregation of Bevacizumab, Ranibizumab and Aflibercept in Dilute Solutions
por: Giannos, Steven A., et al.
Publicado: (2018)

Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?
por: Karagiannis, Dimitrios A, et al.
Publicado: (2009)

Actions of bevacizumab and ranibizumab on microvascular retinal endothelial cells: similarities and differences
por: Deissler, Heidrun L, et al.
Publicado: (2012)

Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting
por: Carneiro, Angela M, et al.
Publicado: (2012)

Switching from Intravitreal Ranibizumab to Bevacizumab for Age-Related Macular Degeneration
por: Yamada, Kisaburo, et al.
Publicado: (2011)

The use of bevacizumab and ranibizumab for branch retinal vein occlusion in medicare beneficiaries
por: Wu, Annie M., et al.
Publicado: (2018)

Effects of Ranibizumab, Bevacizumab, and Aflibercept on Senescent Retinal Pigment Epithelial Cells
por: Chae, Jae-Byoung, et al.
Publicado: (2018)

The effect of intravitreal bevacizumab and ranibizumab on cutaneous tensile strength during wound healing
por: Christoforidis, John B, et al.
Publicado: (2013)

The Effect of Bevacizumab versus Ranibizumab in the Treatment of Corneal Neovascularization: A Preliminary Study
por: Kim, Jin-Hyoung, et al.
Publicado: (2013)

Intravitreal bevacizumab versus ranibizumab: Effects on the vessels of the fellow non-treated eye
por: Peyman, Mohammadreza, et al.
Publicado: (2018)

Comparison of Ranibizumab and Bevacizumab for Macular Edema Associated with Branch Retinal Vein Occlusion
por: Son, Bo Kwon, et al.
Publicado: (2017)

Hydrodynamic Radii of Ranibizumab, Aflibercept and Bevacizumab Measured by Time-Resolved Phosphorescence Anisotropy
por: Hirvonen, Liisa M., et al.
Publicado: (2016)

Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
por: Waizel, Maria, et al.
Publicado: (2017)

Intravitreal bevacizumab-induced exacerbation of proteinuria in diabetic nephropathy, and amelioration by switching to ranibizumab
por: Hanna, Ramy M, et al.
Publicado: (2020)

Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
por: Hamid, Mohamed A., et al.
Publicado: (2021)

Sustained Intraocular Pressure Elevation After Intravitreal Injection of Bevacizumab and Ranibizumab Associated with Trabeculitis
por: Sniegowski, Matthew, et al.
Publicado: (2010)

Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD
por: Avery, Robert L, et al.
Publicado: (2014)

The outcomes of aflibercept therapy in patients with age-related macular degeneration resistant to bevacizumab or ranibizumab
por: Unsal, Erkan, et al.
Publicado: (2018)

Intraocular Pressure Changes after Intravitreal Bevacizumab or Ranibizumab Injection: A Retrospective Study
por: Mansoori, Tarannum, et al.
Publicado: (2021)

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
por: Pessoa, Bernardete, et al.
Publicado: (2021)

Short-term Effectiveness of Intravitreal Bevacizumab vs. Ranibizumab Injections for Patients with Polypoidal Choroidal Vasculopathy
por: Cho, Han Joo, et al.
Publicado: (2012)

Anterior uveitis after treatment of age-related macular degeneration with ranibizumab and bevacizumab: uncommon complication
por: Damasceno, Nadyr, et al.
Publicado: (2012)

Comparison of Systemic Adverse Events Associated with Intravitreal Anti-VEGF Injection: Ranibizumab versus Bevacizumab
por: Hwang, Duck Jin, et al.
Publicado: (2012)

Comparing bevacizumab and ranibizumab for initial reduction of central macular thickness in patients with retinal vein occlusions
por: Singer, Michael A, et al.
Publicado: (2013)

Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD Study
por: Schauwvlieghe, A. M. E., et al.
Publicado: (2016)

Evaluation of the Response to Ranibizumab Therapy following Bevacizumab Treatment Failure in Eyes with Diabetic Macular Edema
por: Hanhart, Joel, et al.
Publicado: (2015)

Antiproliferative, Apoptotic, and Autophagic Activity of Ranibizumab, Bevacizumab, Pegaptanib, and Aflibercept on Fibroblasts: Implication for Choroidal Neovascularization
por: Lytvynchuk, Lyubomyr, et al.
Publicado: (2015)

Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema
por: Alsaedi, Nasser G, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tq4pagthicfo0vu0s6h2tb5ibg